At Conversis we specialise in translating and localising marketing materials, educational content, websites and other digital platforms. Founded in 2003, we supply accurate and appropriately translated communications to clients in the corporate, pharmaceutical, marketing, technology and life sciences industries, among many others.

Built on a reputation for quality and the strong relationships we have developed with both our clients and suppliers, we support organisations in the Pharmaceutical, Oil & Gas, Marketing and Technology industries, among many other sectors.

Company Type
Twitter Account

Dora Wirth Languages

Established in 1962, Dora Wirth Languages Ltd. (DWL) has over 50 years of excellence in global translation solutions for the life science industry. The DWL approach is built on a solid foundation of experience and in-house medical expertise, using DWL’s well-practised and specially formulated procedures for translation, project management and quality control. DWL's business has grown through a dedication and commitment to quality and service. This is acknowledged by DWL's many long-standing clients and is most clearly demonstrated by their recommendation of DWL to others.

Company Type
Twitter Account


OFX is a global company that provides international money transfers at competitive exchange rates for both businesses and consumers. It offers fee-free transactions, 24/7 customer service and rapid round-the-clock transfers thanks to its unique ‘follow-the-sun’ service model. 

We're delighted to introduce our first episode in our video series, OFX Currency Corner. Our resident experts will provide insights on relevant events and trends that impact major currency markets. And what this could mean for you.

In episode one, we look back on the events of 2017 and resultant currency movements. We also take a view on upcoming factors you need to watch out for this month, to help you make the right transfer decisions for your business. 

Company Type
Twitter Account

Silence Therapeutics

Silence Therapeutics develops a new generation of medicines by harnessing the body’s natural mechanism of RNA interference, or RNAi, within its cells.

Our proprietary technology can selectively inhibit any gene in the genome, specifically silencing the production of disease-causing proteins. Using our enabling delivery systems, we have achieved an additional level of specificity by delivering our therapeutic RNA molecules exclusively to target cells. Silence’s proprietary RNA chemistries and delivery systems are designed to improve the stability of our molecules and enhance effective delivery to target cells, providing a powerful modular technology well suited to tackle life-threatening diseases.